BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23669737)

  • 1. Rituximab for the treatment of acute refractory ITP.
    Kim SG; Whyte D; Pashankar FD
    J Pediatr Hematol Oncol; 2014 Apr; 36(3):e149-51. PubMed ID: 23669737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment results of children with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.
    Citak EC; Citak FE
    J Trop Pediatr; 2011 Feb; 57(1):71-2. PubMed ID: 20463085
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
    Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
    Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of an infant with severe acute refractory immune thrombocytopenic purpura using combination therapy including rituximab.
    Iesato K; Hatakeyama N; Yamamoto M; Hori T; Inazawa N; Tsutsumi H; Suzuki N
    Pediatr Blood Cancer; 2009 Aug; 53(2):203-5. PubMed ID: 19301247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP).
    Gómez-Almaguer D
    Hematology; 2012 Apr; 17 Suppl 1():S25-7. PubMed ID: 22507772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
    Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab efficacy in the treatment of children with chronic immune thrombocytopenic purpura.
    Ansari Sh; Rostami T; Yousefian S; Kiumarsi A; Miri-Aliabad G; Ramim T
    Pediatr Hematol Oncol; 2014 Sep; 31(6):555-62. PubMed ID: 25007304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
    Thude H; Gruhn B; Werner U; Schorner U; Häfer R; Zintl F; Barz D
    Acta Haematol; 2004; 111(4):221-4. PubMed ID: 15153715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of refractory immune thrombocytopenia with rituximab in a 10-week-old infant.
    Gray C; Kalumba K; Pati N; Peterson A; Connell TG
    J Pediatr Hematol Oncol; 2013 May; 35(4):e174-7. PubMed ID: 23459375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z; Yang R
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
    Zaja F; Marin L; Chiozzotto M; Puglisi S; Volpetti S; Fanin R
    Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura.
    Lalayanni C; Stavroyianni N; Saloum R; Tsompanakou A; Anagnostopoulos A
    Hematology; 2004 Aug; 9(4):287-9. PubMed ID: 15621736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura.
    Clausen MR; Segel E; Brandsborg M; d'Amore F
    Eur J Haematol; 2011 Mar; 86(3):256-9. PubMed ID: 21166717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura.
    Pasa S; Altintas A; Cil T; Danis R; Ayyildiz O
    J Thromb Thrombolysis; 2009 Apr; 27(3):329-33. PubMed ID: 18311541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y; Wang XM; Mao M; Zhang XY; Fu L; Ai HM; Zhang LX
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recurrent infections in an ITP patient treated with rituximab].
    Rosenberg-Bezalel S; Asher I; Sthoeger Z
    Harefuah; 2012 Nov; 151(11):617-9, 655. PubMed ID: 23367730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics.
    Journeycake JM
    Hematology Am Soc Hematol Educ Program; 2012; 2012():444-9. PubMed ID: 23233617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura.
    Gall B; Yee A; Berry B; Bircham D; Hayashi A; Dansereau J; Hart J
    J Obstet Gynaecol Can; 2010 Dec; 32(12):1167-1171. PubMed ID: 21176329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiopathic thrombocytopenic purpura and myasthenia gravis after fludarabine treatment for chronic lymphocytic leukemia.
    Fujimaki K; Takasaki H; Koharazawa H; Takabayashi M; Yamaji S; Baba Y; Kanamori H; Ishigatsubo Y
    Leuk Lymphoma; 2005 Jul; 46(7):1101-2. PubMed ID: 16019566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.